A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.
Liu X, Guo W, Zhang W, Yin J, Zhang J, Zhu X, Liu T, Chen Z, Wang B, Chang J, Lv F, Hong X, Wang H, Wang J, Zhao X, Wu X, Li J.
Liu X, et al. Among authors: wang h, wang j, wang b.
BMC Cancer. 2017 Mar 14;17(1):188. doi: 10.1186/s12885-017-3174-z.
BMC Cancer. 2017.
PMID: 28288572
Free PMC article.
Clinical Trial.